Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03174795 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

A Phase 1 study of Urinary Tract Infections, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
14
Study locations

NCT03174795: Completed Phase 1 study of Urinary Tract Infections, sponsored by Hoffmann-La Roche.

NCT03174795 is a Phase 1 study of Urinary Tract Infections that has completed, run by Hoffmann-La Roche. The registered enrollment target is 20 participants, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03174795, a Phase 1 study of Urinary Tract Infections, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
14
Study locations

Study Summary

This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.

Conditions Studied

Interventions

  • DRUG RO7079901
  • DRUG Meropenem

Study Locations (14)

Other

  • Semmelweis University, First Dept of Medicine - Budapest
  • Szent Imre Egyetemi Oktatokorhaz - Budapest
  • Kenezy Gyula Korhaz-Rend. Eges. Szol.; Klinikai Farm. Infek. es Allerg. Intezet - Debrecen
  • Liepaja Regional hospital - Liepāja
  • P.Stradina Kliniska Uni Tes Slimnica; Latvian Center of Nephrology - Riga
  • Riga East clinical university hospital - Riga
  • Klinika Urologii Ogólnej: Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu; Urology - Bydgoszcz
  • Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek - Lodz
  • Szpital Kliniczny Dzieciątka Jezus; Oddział Urologii - Warsaw
  • Clinical Center of Serbia; Clinic of Urology - Belgrade
  • Clinical Center Zemun - Belgrade
  • Clinical Hospital Center Bezanijska Kosa - Belgrade

California

  • eStudySite - La Mesa

Florida

  • Jacksonville Center For Clinical Research - Jacksonville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-07-11
Est. Completion 2017-12-16
Phase Phase 1
Hoffmann-La Roche

909 total trials

What the finished NCT03174795 record still lists

NCT03174795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which RO7079901 is the first listed.

NCT03174795 lists 14 locations in 3 states (Other, California, Florida).

Frequently Asked Questions

What is clinical trial NCT03174795 about?

NCT03174795 is a clinical study titled "A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection". This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.

What is the current status of trial NCT03174795?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-07-11. Estimated completion is 2017-12-16.

What conditions does trial NCT03174795 study?

This clinical trial studies the following conditions: Urinary Tract Infections.

What interventions are being tested in trial NCT03174795?

The interventions under investigation include: RO7079901 (DRUG), Meropenem (DRUG).

Who is sponsoring clinical trial NCT03174795?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03174795 being conducted?

This trial has 14 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Tract Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03174795's enrollment target sits among peer trials

20 32nd of 34 higher than 3 of 34 other Urinary Tract Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urinary Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03174795, the US trial registry maintained by the National Library of Medicine. NCT03174795 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.